Volume 12, Number 3—March 2006
Research
Canine Visceral Leishmaniasis, United States and Canada, 2000–2003
Table 1
Serosurvey | IF titer* |
|||||
---|---|---|---|---|---|---|
16 | 32 | 64 | 128 | 256 | >512 | |
First serosurvey (n = 12,411) | ||||||
Cumulative no. seroreactive | 1,667 | 736 | 267 | 190 | 133 | 81 |
Seroprevalence (%) | 13.4 | 5.9 | 2.2 | 1.5 | 1.1 | 0.7 |
Second serosurvey (n = 4,614) | ||||||
Cumulative no. seroreactive | 1,033 | 511 | 195 | 134 | 99 | 62 |
Seroprevalence (%) | 22.4 | 11.1 | 4.2 | 2.9 | 2.1 | 1.3 |
Third serosurvey (n = 1,493) | ||||||
Cumulative no. seroreactive | 438 | 211 | 96 | 67 | 52 | 40 |
Seroprevalence (%) | 29.3 | 14.1 | 6.4 | 4.5 | 3.5 | 2.7 |
Fourth serosurvey (n = 792) | ||||||
Cumulative no. seroreactive | 262 | 141 | 79 | 58 | 51 | 38 |
Seroprevalence (%) | 33.1 | 17.8 | 10.0 | 7.3 | 6.4 | 4.8 |
Fifth serosurvey (n = 571) | ||||||
Cumulative no. seroreactive | 149 | 91 | 58 | 50 | 42 | 33 |
Seroprevalence (%) | 26.1 | 15.9 | 10.2 | 8.8 | 7.4 | 5.8 |
Sixth serosurvey (n = 421) | ||||||
Cumulative no. seroreactive | 115 | 76 | 50 | 42 | 37 | 29 |
Seroprevalence (%) | 27.3 | 18.1 | 11.9 | 10.0 | 8.8 | 6.9 |
*IIF, indirect immunofluorescent assay.
Page created: January 27, 2012
Page updated: January 27, 2012
Page reviewed: January 27, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.